Zelos Therapeutics is a company specializing in innovative treatments for bone disorders and related indications in large, underserved markets. Led by an experienced team of biopharmaceutical executives and funded by leading health care investors, Zelos is advancing a portfolio of product opportunities in Phase 2 and 3 with significant commercial potential into late-stage clinical trials. The company is pursuing programs linked by the common mechanism of stimulating bone formation – specifically parathyroid hormone (PTH) analogs - to provide therapeutic benefit in key indications including osteoporosis, orthopedics, and renal bone disease. Established in 2000, Zelos Therapeutics operates within the Health Care, Health and Wellness, and Pharmaceutical industries. Their last investment was a $2.80M Venture Round investment at 15 August 2011.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $2.80M | - | 15 Aug 2011 | |
| Series B | $42.50M | 4 |
|
19 May 2005 |
| Series A | $11.70M | 3 |
|
01 Jan 2003 |
| Seed Round | $800.00K | - | 01 Dec 2001 |
No recent news or press coverage available for Zelos Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
